Erica Saphire, Zhe Li Salie, Zunlong Ke, Peter Halfmann, Lisa Evans DeWald, Sara McArdle, Ariadna Grinyo, Edgar Davidson, Sharon Schendel, Chitra Hariharan, Michael Norris, Xiaoying Yu, Chakravarthy Chennareddy, Xiaoli Xiong, Megan Heinrich, Michael Holbrook, Benjamin Doranz, Ian Crozier, Kathryn Hastie, Yoshihiro Kawaoka, Luis Branco, Jens Kuhn, John Briggs, Gabriella Worwa, Carl Davis, Rafi Ahmed
Monoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP 1,2 ) are the standard of care for Ebola virus disease (EVD). Anti-GP 1,2 mAbs targeting the stalk and membrane proximal external region (MPER) potently neutralize EBOV in vitro . However, their neutralization mechanism is poorly understood because they target a GP 1,2 epitope that has evaded structural characterization. Moreover, their in vivo efficacy has only been evaluated in the mouse model of EVD. Using x-ray crystallography and cryo-electron tomography of 3A6 complexed with its stalk- GP 1,2 MPER epitope we reveal a novel mechanism in which 3A6 elevates the stalk or stabilizes a conformation of GP 1,2 that is lifted from the virion membrane...
December 22, 2023: Research Square